person · Reporting owner
Garland Jonathan Todd
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Chief Commercial Officer | August 18, 2023 | August 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2023 · Filed August 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,763 |
Ending reported balance
After 2023-08-18 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-08-18 · Exercise / conversion · Acquired 1,951 · Balance 7,838 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2023-08-18 · Tax withholding · Disposed 760 · Balance 7,078 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2023-08-18 · Exercise / conversion · Acquired 2,761 · Balance 9,839 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2023-08-18 · Tax withholding · Disposed 1,076 · Balance 8,763 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,462 |
Reported balance
After 2023-08-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-18 · Exercise / conversion · Disposed 1,951 · Balance 21,462 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 39,579 |
Reported balance
After 2023-08-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-18 · Exercise / conversion · Disposed 2,761 · Balance 39,579 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
F4: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NanoString Technologies Inc
Report date May 06, 2024 · Filed May 08, 2024
Section 16 reporting ended · disclosed 2024-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2024-05-06 transaction · row 1
1 source rowRow 1 · 2024-05-06 · Exercise / conversion · Acquired 200,000 · Balance 200,000 F1: The shares have not been delivered to the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-06 · Exercise / conversion · Disposed 200,000 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares have not been delivered to the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2024 Filed May 8, 2024 20:48 UTC | NanoString Technologies Inc NSTG · Entity 15988 | Exercise / conversionRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001401708-24-000086 · wk-form4_1715215692.xml · derivative · entry 2 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F3 · derivative.exercise_date: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. F3 · derivative.expiration_date: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:48 UTC | NanoString Technologies Inc NSTG · Entity 15988 | Exercise / conversionCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001401708-24-000086 · wk-form4_1715215692.xml · nonDerivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares have not been delivered to the reporting person. Read SEC document |
| August 28, 2023 Filed Aug 28, 2023 16:26 UTC | NanoString Technologies Inc NSTG · Entity 15988 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001401708-23-000210 · wk-form4_1693254360.xml · derivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2 · derivative.exercise_date: 1/3 of the RSUs vest on or following the first anniversary of August 28, 2023 (the "RSU Vesting Commencement Date"), and 1/3 of the RSUs vest annually each year on or after the second and third anniversary of the RSU Vesting Commencement Date. F2 · derivative.expiration_date: 1/3 of the RSUs vest on or following the first anniversary of August 28, 2023 (the "RSU Vesting Commencement Date"), and 1/3 of the RSUs vest annually each year on or after the second and third anniversary of the RSU Vesting Commencement Date. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · derivative · entry 6 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,579 Underlying: Common Stock · 2,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · derivative · entry 5 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,462 Underlying: Common Stock · 1,951 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,076 | $8.46 | $9,102.96 |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · nonDerivative · entry 4 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,763 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · nonDerivative · entry 3 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 760 | $8.46 | $6,429.60 |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · nonDerivative · entry 2 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,078 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:10 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046826 · doc4.xml · nonDerivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · derivative · entry 6 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,340 Underlying: Common Stock · 1,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · derivative · entry 5 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,413 Underlying: Common Stock · 7,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 717 | $6.69 | $4,796.73 |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · nonDerivative · entry 4 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,887 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · nonDerivative · entry 3 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 3,040 | $6.69 | $20,337.60 |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · nonDerivative · entry 2 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,764 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 19:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031260 · doc4.xml · nonDerivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 19:45 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 44,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016977 · doc4.xml · derivative · entry 2 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,180 Underlying: Common Stock · 44,180 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 19:45 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 66,773 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016977 · doc4.xml · derivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,773 Underlying: Common Stock · 66,773 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 31,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025897 · doc4.xml · derivative · entry 2 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,217 Underlying: Common Stock · 31,217 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 46,971 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001209191-22-025897 · doc4.xml · derivative · entry 1 Garland Jonathan Todd · CIK 0001924824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,971 Underlying: Common Stock · 46,971 shares Expires 2032-04-25 F1 · derivative.exercise_date: The option will vest as follows: 25% of the total shares underlying the option shall vest on April 25, 2023 and 1/48 of the total shares underlying the option shall vest each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.